Analytical range LOQ [Bioanalytics]

posted by Farmacevt – North Macedonia, 2021-12-22 23:02 (849 d 14:43 ago) – Posting: # 22711
Views: 2,087

Thanks,
But when you say:

❝ At one extreme you may need to eliminate those subject periods that are affected, which may mean a complete loss of a subject for stats if this is a 222BE design, since only subjects who contribute with T and R should be in the stats analysis.


What is the rational for eliminating those subjects? According to my opinion excluding these subjects can not show that the subjects might have had pre-dose concentration below the LOQ with the given method. It will only reduce the power of the study, isn't it?


Edit: Standard quotes restored; see also this post #8[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,655 registered users;
101 visitors (0 registered, 101 guests [including 4 identified bots]).
Forum time: 14:45 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5